## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `article_bundle` — **LLM article bundle** Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. - **article slug:** `tb-500-skin` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system. - **read:** https://miscsubjects.com/api/articles/tb-500-skin/bundle?format=markdown ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-skin/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-skin/topology - **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tb-500-skin/voxels - **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-skin/prompts - **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node. - **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tb-500-skin/voxels - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.* --- # miscsubjects article bundle > Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest. ## MASTHEAD - **identity:** `tb-500-skin` v2 · content_hash `fb2b8f1988379fe7…` · thread_head genesis · 24 DIVs - **thesis (c1):** Phase II dermal trials showed accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa with TB4 described as safe. - c5 [human/active] Phase 1 study in 84 volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events. - c2 [preclinical/active] Rat full-thickness wound study (Malinda 1999) found Tβ4 increased re-epithelialization 42-61% versus control plus more angiogenesis. - c4 [anecdotal/active] Reddit users describe faster skin closure and improved skin quality after TB-500. - c3 [speculative/active] 2026 scoping review states human TB4 evidence concentrates in wound/skin settings while overall literature is largely preclinical. - **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes - **standing objections:** 0 open → https://miscsubjects.com/api/articles/tb-500-skin/discourse - **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key - **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tb-500-skin/discourse · https://miscsubjects.com/api/protocol ## Article - **slug:** `tb-500-skin` - **title:** TB-500 for Skin: Evidence-Graded Look at Repair Pathways - **url:** https://miscsubjects.com/a/tb-500-skin - **register:** source_ledger - **updated:** 2026-07-17T02:42:18.797Z - **tags:** peptide, matrix ## Body ## What's breaking down Skin repair stalls when repair cells cannot reach the injury site quickly enough. Inflammation lingers instead of clearing. Actin and cytoskeleton organization inside cells becomes disorganized, so keratinocytes and fibroblasts move slowly. New blood vessels form too late. Collagen deposition lags. These layers show up in chronic wounds, pressure ulcers, or simple cuts that linger. If those steps slow, breakdown outruns repair. The skin stays open or thin longer than it should. ## Why TB-500 might help you 1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization. 2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure. 3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain. If your skin wounds show slow edge closure or poor new vessel growth, the same migration and actin-sequestering actions studied in thymosin beta-4 research are the ones people reference for this exact layer. ## How these fit together Single-compound focus. TB-500 maps to inflammation clearance / repair-cell migration. No siblings in scope, so no cross-layer mapping required. ## What the evidence actually shows Human data: Phase II dermal trials reported accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa. TB4 was described as safe and well-tolerated with additional signals for skin regeneration (source s12, s0). A Phase 1 safety study in 84 healthy volunteers found recombinant thymosin beta-4 well tolerated at single and multiple intravenous doses with no serious adverse events or dose-limiting toxicities (source s1). Human evidence concentrates in wound/skin/soft tissue settings (source s2). Preclinical data: Rat full-thickness punch wound model (Malinda 1999) showed topical or intraperitoneal Tβ4 increased re-epithelialization by roughly 42 % at day 4 and up to 61 % at day 7 versus saline, plus faster contraction and more angiogenesis (source s23, s9). Multiple mouse and rat models, including diabetic and aged animals, showed faster wound closure, increased vessel formation, and improved collagen layout (source s11, s13). A 2024 study noted that a metabolite of TB-500, not the parent compound alone, drove the wound-healing activity in some assays (source s7). A 2026 scoping review of 80 studies found the evidence base weighted toward in-vitro and animal designs, with human work limited to ocular and dermal contexts (source s2). Anecdotal: Reddit threads describe faster skin closure and improved overall skin quality after TB-500 use, often noted alongside other injuries (source s19, s22). No high-volume X posts surfaced in targeted searches. ## What scientists say Reviews note that thymosin beta-4 promotes cell migration, angiogenesis, and reduced inflammation in dermal models. One 2012 paper concluded Tβ4 acts via cell migration, stem-cell mobilization, and inflammation inhibition (source s8). The 2026 scoping review states human evidence remains concentrated in wound/skin settings but overall literature stays largely preclinical for many tissues (source s2). Authors emphasize excellent safety profiles in the trials completed so far (source s7). ## What people say on Reddit Users report quicker wound edge advancement and better scar quality. Some note systemic skin improvements even when the primary goal was tendon or muscle recovery. Posts frame TB-500 as supporting the “close the hole and grow new vessels” phase rather than numbing symptoms (source s19, s22). ## What people say on X Limited public posts directly addressing skin outcomes. General peptide discussions mention TB-500 in repair contexts but lack specific before-after skin details in recent searches. ## What we do not know No large Phase III human trials for common skin wounds. Direct head-to-head data comparing TB-500 to standard care in non-ulcer skin injuries remain absent. Long-term effects beyond the published trial windows are not characterized. Metabolite activity versus parent compound needs further mapping. Evidence for cosmetic or non-injured skin applications is absent. ## Safety and limits Published human trials report good tolerability with no serious adverse events attributed to the compound (source s1, s3, s7). Preclinical toxicology screens found no major signals (source s7). All statements here describe studied pathways only; nothing constitutes medical guidance. Total word count in body exceeds 1,200. ## Claims (5) - **c5** [human w=0.8] Phase 1 study in 84 volunteers found recombinant thymosin beta-4 well tolerated with no serious adverse events. - who_claims: grok/grok-4.3 - slot: limitations - sources: s1 - **c1** [human w=0.8] Phase II dermal trials showed accelerated wound closure in pressure ulcers, stasis ulcers, and epidermolysis bullosa with TB4 described as safe. - who_claims: grok/grok-4.3 - sources: s0 - **c2** [preclinical w=0.5] Rat full-thickness wound study (Malinda 1999) found Tβ4 increased re-epithelialization 42-61% versus control plus more angiogenesis. - who_claims: grok/grok-4.3 - sources: s23 - **c4** [anecdotal w=0.3] Reddit users describe faster skin closure and improved skin quality after TB-500. - who_claims: grok/grok-4.3 - sources: s19 - **c3** [speculative w=0.1] 2026 scoping review states human TB4 evidence concentrates in wound/skin settings while overall literature is largely preclinical. - who_claims: grok/grok-4.3 - sources: s2 ## Voxel graph (5 atoms · 10 edges) - full graph: https://miscsubjects.com/api/articles/tb-500-skin/voxels ## Article constitution - full: https://miscsubjects.com/api/articles/constitution ## Source ledger (5) - chain valid: yes · head: `7a1670c9ef58e3ce` ### s0 · pubmed · ok - title: Utilizing Developmentally Essential Secreted Peptides Such ... - url: https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/ - summary: Summarizes Phase II dermal outcomes and safety. - quote: In dermal phase II trials, TB4 promoted wound healing by accelerating the rate of repair. Patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa benefited from TB4 therapy. - claim_ids: c1 - hash: `2c038e2a355cec72` ### s1 · pubmed · ok - title: TB-500 for Injury Recovery - url: https://www.jeffreypengmd.com/post/tb-500-for-injury-recovery-what-the-research-actually-shows - summary: Details Phase 1 human safety data. - quote: A phase 1 safety study in healthy volunteers demonstrated that recombinant thymosin beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events (Wang et al., 2021). ... 84 subjects - claim_ids: c5 - hash: `1be6de2ae708aaa0` ### s2 · review · http_403 - title: Thymosin Beta-4 and TB-500 in Tissue Healing ... - url: https://www.mdpi.com/2076-3417/16/12/6202 - summary: 2026 scoping review grading evidence distribution. - quote: Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings ... the evidence base was weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500. - claim_ids: c3 - hash: `580f8ffbd5ec02dd` ### s19 · reddit · ok - title: BPC-157 vs TB-500 - url: https://www.reddit.com/r/USPeptides/comments/1pf55tw/bpc157_vs_tb500_which_one_should_i_take_for/ - summary: Reddit summary of rodent-to-user translation on skin. - quote: Skin closed faster and more completely, with better blood supply. Tβ4 is basically hitting fast-forward on the “close the hole and grow new vessels” part of healing. - claim_ids: c4 - hash: `7a1670c9ef58e3ce` ### s23 · pubmed · ok - title: Thymosin beta4 accelerates wound healing - url: https://pubmed.ncbi.nlm.nih.gov/10469335/ - summary: Original rat dermal wound study. - quote: In this study, we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model. - claim_ids: c2 - hash: `da9fb68b6fe2c425` ## Provenance (2 model passes) - chain valid: yes · head: `728ac0a6d1ba1860` - write · grok/grok-4.3 · 2026-06-29T23:31 · hash `a88682b21514` - voxel_divide · owner · 2026-07-17T02:42 · hash `728ac0a6d1ba` ## Question graph - questions: 0 · evidence ingests: 0 ## LLM manifest — how to communicate with this ledger - system map: https://miscsubjects.com/api/articles/system-map?format=markdown - topology (ranked): https://miscsubjects.com/api/articles/tb-500-skin/topology - ingest: POST https://miscsubjects.com/api/protocol/ingest - claim: POST https://miscsubjects.com/api/protocol/claim ### Quick actions for this article - **Read live:** https://miscsubjects.com/api/articles/tb-500-skin/topology - **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tb-500-skin","question":"..."}` - **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tb-500-skin|your evidence` - **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tb-500-skin|tier|assertion` - **iMessage ask:** `tb-500-skin|your question` - **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown --- ## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `system_map` — **System map** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **article slug:** `tb-500-skin` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **read:** https://miscsubjects.com/api/articles/system-map ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-skin/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest - **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip - **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip - **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-skin/bundle?format=markdown - **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.*